• Home
  • Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

Author List
Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A
Publication
PloS one
Publication ID (Profile URL)
https://researcherprofiles.org/profile/102292389
Publication Year
2018
PubMed ID
29408938
Publication Title
Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLoS One. 2018; 13(2):e0191953.